Sacuva 100 Tablet

About Sacuva 100 49 mg + 51 mg Tablet

Sacuva 100 49 mg + 51 mg is a tablet product of The ACME Laboratories Ltd. that contains Sacubitril + Valsartan. It is also used for symptomatic heart failure with left ventricular systolic dysfunction in children aged one year and older.

There are 25 brands of Sacubitril + Valsartan listed in Bangladesh. The lowest listed price is Arnis 24 mg+26 mg Tablet at ৳ 35.00 per unit.

What is Sacuva 100 49 mg + 51 mg Tablet?

Made by The ACME Laboratories Ltd., Sacuva 100 is a tablet whose active ingredient is Sacubitril + Valsartan. It contains two active substances, sacubitril and valsartan, in a strength of 49 mg + 51 mg. This combination belongs to a group of heart failure medicines. Whether it suits you is a decision for your doctor.

Uses of Sacuva 100

It is also used for symptomatic heart failure with left ventricular systolic dysfunction in children aged one year and older. Sacuva 100 is used in adults with chronic heart failure and reduced ejection fraction to lower the risk of cardiovascular death and hospitalisation for heart failure. It helps lower the risk of dying from heart problems and reduces the chance of needing hospital care for heart failure. The doctor decides whether it is suitable and the dose and course.

How to use Sacuva 100

Swallow the tablet with water. Sacuva 100 is taken by mouth. Keep the medicine out of reach of children. The dose and how often you take it will be decided by your doctor based on your condition and other medicines you take. If you miss a dose, ask your doctor or pharmacist what to do rather than doubling the next one.

Side effects of Sacuva 100

Side effects that need attention include swelling of the face, lips, tongue or throat (angioedema), low blood pressure with dizziness or fainting, worsening kidney function, raised potassium, cough and dizziness. Do not ignore severe symptoms. Tell your doctor straight away if you have trouble breathing, swelling, or feel very dizzy or faint. Tell your doctor if you notice any side effects or if they bother you.

Safety and precautions

Sacuva 100 must not be used if you have had angioedema related to an ACE inhibitor or ARB, or if you have hereditary angioedema. Before starting, tell your doctor about any kidney or liver problems, low blood pressure, or high potassium. Women who can become pregnant should use effective contraception and tell their doctor if they become pregnant. Tell your doctor about all medicines you take, including NSAIDs, potassium-sparing diuretics and lithium.

Frequently asked questions

What does Sacuva 100 treat?

It is also used for symptomatic heart failure with left ventricular systolic dysfunction in children aged one year and older. Sacuva 100 is used in adults with chronic heart failure and reduced ejection fraction to lower the risk of cardiovascular death and hospitalisation for heart failure.

How is Sacuva 100 used?

Swallow the tablet with water. Sacuva 100 is taken by mouth.

What are the side effects of Sacuva 100?

Side effects that need attention include swelling of the face, lips, tongue or throat (angioedema), low blood pressure with dizziness or fainting, worsening kidney function, raised potassium, cough and dizziness. Do not ignore severe symptoms.

Can I use Sacuva 100 in pregnancy or while breastfeeding?

Sacuva 100 must not be used if you have had angioedema related to an ACE inhibitor or ARB, or if you have hereditary angioedema. Before starting, tell your doctor about any kidney or liver problems, low blood pressure, or high potassium.

Indications

This is indicated:
  • To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
  • For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
  • ... Read more
This is indicated:
  • To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
  • For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
  • This is usually administered in conjunction with other heart failure therapies, in place of an angiotensin-converting enzyme inhibitor (ACEi) or other ARB.

Pharmacology

This tablet contains a neprilysin inhibitor, sacubitril, and an angiotensin receptor blocker, valsartan. This tablet inhibits neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and blocks the angiotensin II type-1 (AT1 ) receptor via valsartan. The cardiovascular and renal effects of this tablet in heart failure patients are attributed to the increased levels of peptides that are degraded by neprilysin, such as natriuretic peptides, by LBQ657, and the simultaneous inhibition of the effects of angiotensin II by valsartan. Valsartan inhibits the effects of angiotensin II by selectively blocking the AT1 receptor, and also inhibits angiotensin II-dependent aldosterone release.

Dosage & Administration

Adult Heart Failure: The recommended starting dose is 49/51 mg orally twice daily. Double the dose after 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily, as tolerated by the patient.

Reduce the starting dose to 24/26 mg twice daily for:
  • Patients not currently taking an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) or previously taking a low dose of these agents.
  • Patients with severe renal impairment.
  • Patients with moderate hepatic impairment.
Pediatric Heart Failure: Refer to Table 1 for the recommended dose for pediatric patients aged one year and older. Take the recommended dose orally twice daily. Adjust pediatric patient doses every 2 weeks, as tolerated by the patient.

Recommended Dose Titration-

Pediatric Patients Less than 40 kg:
  • Starting: 1.6 mg/kg
  • Second: 2.3 mg/kg
  • Final: 3.1 mg/kg
Pediatric Patients At least 40 kg, less than 50 kg:
  • Starting: 24/26 mg
  • Second: 49/51 mg
  • Final: 49/51 mg
Pediatric Patients At least 50 kg:
  • Starting: 49/51 mg
  • Second: 72/78 mg
  • Final: 97/103 mg

Interaction

Dual Blockade of the Renin-Angiotensin-Aldosterone System: Should not be used with an ACEi, aliskiren in patients with diabetes, and use with an ARB should be avoided.
Potassium-sparing Diuretics: Serum potassium level may be increased.
NSAIDs: Risk of renal impairment may be increased.
Lithium: Increased risk of lithium toxicity.

Contraindications

This combination is contraindicated:
  • In patients with hypersensitivity to any component
  • In patients with a history of angioedema related to previous ACE inhibitor or ARB therapy 
  • With concomitant use of ACE inhibitors. Do not administer within 36 hours of switching from or to an ACE inhibitor 
  • With concomitant use of aliskiren in patients with diabetes

Side Effects

The most common side effects are Angioedema, Hypotension, Impaired Renal Function, Hyperkalemia, Cough, Dizziness.

Pregnancy & Lactation

Pediatric Use: Safety and effectiveness have not been established in pediatric patients less than 1 year of age.

Geriatric Use: No relevant pharmacokinetic differences have been observed in elderly (>65 years) or very elderly (>75 years) patients compared to the overall population.
 
Hepatic Impairment: No dose adjustment is required when administering this tablet to patients with mild hepatic impairment (Child-Pugh A classification). This tablet is not recommended in patients with severe hepatic impairment, as no studies have been conducted in these patients.

Renal Impairment: No dose adjustment is required in patients with mild (eGFR 60 to 90 ml/min/1.73 m2) to moderate (eGFR 30 to 60 ml/min/1.73 m2) renal impairment. The recommended starting dose in patients with severe renal impairment (eGFR <30 ml/min/1.73 m2) is 24/26 mg twice daily.

Precautions & Warnings

This tablet may cause angioedema and must not be used in patients with a known history of angioedema related to previous ACEi or ARB therapy and in patients with hereditary angioedema.

This tablet lowers blood pressure and may cause symptomatic hypotension. Closely monitor serum creatinine, and down-titrate or interrupt this tablet in patients who develop a clinically significant decrease in renal function. In patients with renal artery stenosis, monitor renal function.

Monitor serum potassium periodically and treat appropriately, especially in patients with risk factors for hyperkalemia such as severe renal impairment, diabetes, hypoaldosteronism, or a high potassium diet. Dosage reduction or interruption of this tablet may be required.

Overdose Effects

Limited data are available with regard to overdosage in human subjects with this tablet. In healthy volunteers, a single dose of this tablet 583 mg sacubitril/617 mg valsartan, and multiple doses of 437 mg sacubitril/463 mg valsartan (14 days) have been studied and were well tolerated. Hypotension is the most likely result of overdosage due to the blood-pressure-lowering effects of this tablet. Symptomatic treatment should be provided. This tablet is unlikely to be removed by hemodialysis because of high protein binding.

Storage Conditions

Keep in a dry place and store below 30°C. Protect from moisture and keep out of the reach of children.

Alternative brands of Sacubitril + Valsartan

Other brands with the same generic name, cheapest first.

See all 25 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.